Also trades as: ADAP (NASDAQ) · $vol 5M
ADAPY OTC
Adaptimmune Therapeutics plc
1W: +45.1%
1M: +48.0%
3M: -5.1%
YTD: +5.6%
1Y: -69.5%
3Y: -95.4%
5Y: -99.4%
$0.04
-0.00 (-2.63%)
Weekly Expected Move ±21.4%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$178M
+195.3% ▲
5Y CAGR: +175.5%
Gross Profit
$178M
+252.9% ▲
Operating Income
-$69M
+50.2% ▲
Net Income
-$71M
+37.8% ▲
EPS (Diluted)
$-0.28
+50.4% ▲
EBITDA
-$53M
+58.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $4M | $6M | $27M | $60M | $178M |
| YoY Growth | +252.8% | +55.4% | +341.5% | +122.0% | +195.3% |
| Cost of Revenue | $92M | $111M | $128M | $10M | $70K |
| Gross Profit | -$88M | -$105M | -$101M | $50M | $178M |
| Gross Margin | -2213.5% | -1706.6% | -370.5% | 83.6% | 100.0% |
| R&D Expenses | $92M | $111M | $128M | $127M | $149M |
| SG&A Expenses | $46M | $57M | $63M | $72M | $81M |
| Operating Expenses | $137M | $168M | $191M | $188M | $247M |
| Operating Income | -$133M | -$162M | -$164M | -$138M | -$69M |
| Operating Margin | -3370.5% | -2638.6% | -604.0% | -229.0% | -38.6% |
| Interest Expense | $0 | $0 | $0 | $0 | $3M |
| Income Before Tax | -$130M | -$157M | -$163M | -$113M | -$67M |
| Tax Expense | $162K | $791K | $2M | $1M | $4M |
| Net Income | -$130M | -$158M | -$165M | -$114M | -$71M |
| Net Margin | -3286.8% | -2571.0% | -609.5% | -188.9% | -39.8% |
| EPS (Diluted) | $-0.90 | $-1.02 | $-1.02 | $-0.57 | $-0.28 |
| EBITDA | -$126M | -$156M | -$156M | -$128M | -$53M |
| Shares Outstanding | 142M | 156M | 161M | 201M | 252M |